Safety and Efficacy of EVT 101 in Treatment-Resistant Depression
Public ClinicalTrials.gov record NCT01128452. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 4-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Investigate the Safety and Efficacy of EVT 101 as Monotherapy in Patients With Treatment-Resistant Major Depression
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is a 4-week, randomized, double-blind, parallel-group, placebo-controlled monotherapy study in patients with treatment-resistant major depression. After confirmation of treatment-resistance in a prospective treatment period with citalopram, each patient will be treated with either EVT 101 once daily or placebo for 28 consecutive days.
Study identification
- NCT ID
- NCT01128452
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 8 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 55 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 2010 (Type not available)
- Primary completion
- Mar 2011 (Actual)
- Completion
- Mar 2011 (Actual)
- Last update posted
- Mar 28, 2016
2010 – 2011
United States locations
- U.S. sites
- 14
- U.S. states
- 10
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Evotec Study Site 6 | Oceanside | California | — | — |
| Evotec Study Site 19 | San Diego | California | — | — |
| Evotec Study Site 15 | Tampa | Florida | — | — |
| Evotec Study Site 4 | Atlanta | Georgia | — | — |
| Evotec Study Site 14 | Smyrna | Georgia | — | — |
| Evotec Study Site 3 | Beachwood | Illinois | — | — |
| Evotec Study Site 2 | Oak Brook | Illinois | — | — |
| Evotec Study Site 1 | Baltimore | Maryland | — | — |
| Evotec Study Site 8 | Flowood | Mississippi | — | — |
| Evotec Study Site 5 | Willingboro | New Jersey | — | — |
| Evotec Study Site 9 | New York | New York | — | — |
| Evotec Study Site 13 | Oklahoma City | Oklahoma | — | — |
| Evotec Study Site 7 | Dallas | Texas | — | — |
| Evotec Study Site 12 | Houston | Texas | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01128452, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 28, 2016 · Synced Oct 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01128452 live on ClinicalTrials.gov.